SB 743921

Drug Profile

SB 743921

Alternative Names: SB-743921; SB-921

Latest Information Update: 21 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytokinetics
  • Class Antineoplastics; Benzopyrans; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 Dec 2009 Interim adverse events & efficacy data from the phase I/II CY 2121 trial in Hodgkin's disease & Non-Hodgkin's lymphoma presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
  • 02 Jun 2009 Interim efficacy & adverse events data from the phase I portion of a phase I/II trial in non-Hodgkin's lymphoma presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top